Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

Background: Programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitions are being strongly recommended for the treatment of various cancers, while the efficacy of PD-1/PD-L1 inhibitions varies from individuals. It is urgent to explore some biomarkers to screen the most appro...

Full description

Bibliographic Details
Main Authors: Jiaxin Zhu, Tiantian Zhang, Jiahao Li, Junming Lin, Wenhua Liang, Wenjie Huang, Ning Wan, Jie Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Pharmacology
Subjects:
tumor mutation burden
cancer
PD-1/PD-L1 inhibitions
biomarker
meta-analysis
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00673/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00673/full

Similar Items